Business
Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise
Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\n Results show a mini dose (150 µg) of RTU glucagon prevents\n Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high\n intensity aerobic exercise in a clinical research setting\n \n\n CHICAGO--(BUSINESS WIRE)--\n Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical\n company leveraging its novel technology platforms to develop and\n commercialize ready-to-use injectable and infusible drug formulations,\n today announced positive topline results from the in-clinic stage of a\n Phase 2 study of its developmental ready-to-use (RTU) glucagon for the\n prevention of hypoglycemia during and after moderate-to-high intensity\n aerobic exercise in adults with Type 1 diabetes mellitus (T1D).\n \n \n Results from the in-clinic stage of the Phase 2 Exercise-Induced\n Hypoglycemia (EIH) study show that a mini dose of RTU glucagon was\n adequate to maintain normal blood glucose levels during prolonged,\n moderate-to-intense aerobic exercise. Episodes of hypoglycemia were\n observed both during and after the prescribed exercise session. Overall,\n there were more EIH episodes among subjects who received standard of\n care (placebo plus 50% insulin pump reduction) than subjects who\n received RTU glucagon plus 50% insulin pump reduction. The use of\n glucose tablets to treat hypoglycemia during and after exercise was less\n with RTU glucagon when compared to standard of care. Treatment-emergent\n adverse events with a mini dose of RTU glucagon were comparable to\n placebo, including negligible injection site reactions. In this phase of\n the study, mini doses of RTU glucagon were safe and well tolerated, and\n no serious adverse events occurred.\n \n \n “For people with Type 1 diabetes, prolonged and vigorous aerobic\n exercise can be dangerous if not planned out and executed carefully. The\n current standard of care includes multiple preparation steps, such as\n insulin pump reduction well before exercise, and eating high glucose\n foods before, during, and after the exercise session. These steps can be\n a barrier to exercise, and therefore, many people with diabetes do not\n achieve 2 ½ hours of aerobic exercise per week as per ADA guidelines,”\n said Paul R. Edick, Xeris’ Chairman and CEO. “Our goal with this study\n is to show that a mini dose (150 µg) of Xeris’ liquid stable glucagon,\n administered imm...